Multivalent vaccines for rabies virus and filoviruses

A multivalent vaccine effective to protect against both rabies and a filovirus, comprising a recombinant rabies virus vector that expresses at least one filovirus glycoprotein or an immunogenic fragment thereof.

A virus vaccine comprising an attenuated recombinant rabies virus vector which expresses the Ebola glycoprotein, wherein the virus vaccine is protective against both a rabies virus infection and an Ebolavirus infection.

A method of inducing an immune response protective against a filovirus and a rabies virus in a subject, comprising administering to the subject a therapeutically effective amount of a multivalent vaccine comprising a recombinant rabies virus vector that expresses at least one filovirus glycoprotein or an immunogenic fragment thereof.

27-32. (canceled)

A method of inducing neutralizing antibodies against a filovirus and/or a rabies virus in a subject infected with or having been exposed to either or both of said viruses, comprising administering to the subject a therapeutically effective amount of a multivalent vaccine comprising a recombinant rabies virus vector that expresses at least one filovirus glycoprotein or an immunogenic fragment thereof, or

• A method of treating a subject infected with a filovirus and/or a rabies virus, comprising administering to the subject a therapeutically effective amount of a multivalent vaccine comprising a recombinant rabies virus vector that expresses at least one filovirus glycoprotein or an immunogenic fragment thereof, wherein said vaccine induces an effective immune response against one or both of said viruses.

34-45. (canceled)

A live, replication-competent, rabies virus based vector expressing an Ebola glycoprotein, or

• A live, replication-deficient, rabies virus based vector expressing an Ebola glycoprotein.

47-51. (canceled)